B. Laleu

A fast-killing tyrosine amide ((S)-SW228703) with blood and liver-stage antimalarial activity associated with the Cyclic Amine Resistance Locus (PfCARL)

This paper identifies (S)-SW228703, a tyrosine amide with fast-killing antimalarial activity against blood and liver stages of Plasmodium falciparum, and links resistance to mutations in PfCARL and PfACT.

A small-molecule myosin inhibitor as a targeted multi-stage antimalarial

This paper develops a small-molecule myosin inhibitor, KNX-115, effective against multiple stages of Plasmodium infection with high selectivity and potency.

Replenishing the malaria drug discovery pipeline: Screening and hit evaluation of the MMV Hit Generation Library 1 (HGL1) against asexual blood stage Plasmodium falciparum, using a nano luciferase reporter read-out

The paper screens a compound library against Plasmodium falciparum using a nanoluciferase assay, identifying 33 high-quality hits for antimalarial drug development.

Rudimentary Structure-Activity-Relationship study of the MMV Pathogen Box compound MMV675968 (2,4-diaminoquinazoline) unveils novel inhibitors of Trypanosoma brucei brucei DHFR enzyme

This study identifies two potent analogs of MMV675968 that inhibit Trypanosoma brucei DHFR with higher potency and selectivity, showing potential as new antitrypanosomal drug candidates.

Screening the MMV Open Access Pathogen box unveils novel and potent inhibitors of Amoebiasis agent: Entamoeba histolytica

The paper screens the MMV Pathogen Box to identify novel anti-Entamoeba histolytica compounds with low micromolar activity and improved potency through structure-activity relationship studies.

Addressing the Most Neglected Diseases through an Open Research Model: the Discovery of Fenarimols as Novel Drug Candidates for Eumycetoma

This paper identifies new drug candidates for eumycetoma by screening 800 compounds and testing their in vitro and in vivo activity against Madurella mycetomatis, using an open-source approach to accelerate drug discovery.